Affimed Announces Pricing of Public Offering of Common Stock
Affimed N.V. (AFMD)
Last affimed n.v. earnings: 11/19 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
affimed.com/investor-relations.php
Company Research
Source: GlobeNewswire
Heidelberg, Germany February 13, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the pricing of its previously announced public offering of 11,500,000 of its common shares at a public offering price of $2.00 per common share. In addition, Affimed has granted the underwriters a 30-day option to purchase up to an additional 1,725,000 common shares at the public offering price less underwriting discounts. After deducting the underwriting discounts, the net proceeds of the public offering are expected to be approximately $21.6 million. The offering is expected to close on or about February 15, 2018, subject to customary closing conditions. Jefferies LLC and Wells Fargo Securities, LLC are acting as joint book-running managers. A shelf registration statement relating to these securities filed with the Securities and Exchange Commission (SEC) was declared effe
Show less
Read more
Impact Snapshot
Event Time:
AFMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AFMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AFMD alerts
High impacting Affimed N.V. news events
Weekly update
A roundup of the hottest topics
AFMD
News
- Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024GlobeNewswire
- Affimed Announces 1-for-10 Reverse Stock SplitGlobeNewswire
- Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung CancerGlobeNewswire
- Affimed Announces Leadership Change and Organizational RestructuringGlobeNewswire
- Global Natural Killer Cells Therapeutics Research Report 2023: Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2022 and 2023-2028 [Yahoo! Finance]Yahoo! Finance
AFMD
Earnings
- 11/14/23 - Beat
AFMD
Sec Filings
- 3/11/24 - Form 6-K
- 3/6/24 - Form 6-K
- 2/14/24 - Form SC
- AFMD's page on the SEC website